Latest advances in the cannabinoids

• GAONI Y, MECHOULAM R: Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. (1964) 86:1646-1647.
   Web of Science ®Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned DNA. Nature (1990) 346:561-564.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharm. (1995) 50:83-90.
   PubMed Web of Science ®Google Scholar
• HANUS L, ABU-LAFI S, FRIDE E et al.: 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA (2001) 98:3662-3665.
   PubMed Web of Science ®Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
   PubMed Web of Science ®Google Scholar
• WILSON RI, NICOLL RA: Endocannabinoid signalling in the brain. Science (2002) 296:678-682.
   PubMed Web of Science ®Google Scholar
• HOWLETT AC, BARTH F, BONNER TI et al.: Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:203-217.
   PubMedGoogle Scholar
• WHITESIDE GT, LEE GP, VALENZANO KJ: The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr. Med. Chem. (2007) 14:917-936.
   PubMed Web of Science ®Google Scholar
• BREIVOGEL CS, GRIFFIN G, DI MARZO V, MARTIN BR: Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. (2001) 60:155-163.
   PubMed Web of Science ®Google Scholar
• RYBERG E, LARSSON N, SJÖGREN S et al.: The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. (2007):Doi10.1038/sj.bjp.0707460.
   PubMedGoogle Scholar
• WANG H, DEY SK, MACCARRONE M: Jekyll and Hyde: two faces of cannabinoid signalling in male and female fertility. Endocr. Rev. (2006) 27:427-448.
   PubMed Web of Science ®Google Scholar
• YAO BB, MUKHERJEE S, FAN Y et al.: In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br. J. Pharmacol. (2006) 149:145-154.
   PubMed Web of Science ®Google Scholar
• BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Cur. Med. Chem. (1999) 6:745-755.
   PubMed Web of Science ®Google Scholar
• GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (2000) 12:1529-1538.
   Google Scholar
• ADAM J, COWLEY P: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2002) 12:1475-1489.
   Web of Science ®Google Scholar
• HERZOG DL: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2004) 14:1435-1452.
   Google Scholar
• MUCCIOLI GC, LAMBERT DM: Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Patents (2006) 16:1405-1423.
   Web of Science ®Google Scholar
• TUCCI SA, HALFORD JCG, HARROLD JA, KIRKHAM TC: Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem. (2006) 13:2669-2680.
   PubMed Web of Science ®Google Scholar
• KLEIN TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immun. (2005) 5:400-411.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. (1995) 56:1941-1947.
   PubMed Web of Science ®Google Scholar
• LANGE JH, KRUSE CG: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10:693-702.
   PubMed Web of Science ®Google Scholar
• CARPINO PA, GRIFFITH DA, SAKYA S et al.: New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorg. Med. Chem. Lett. (2006) 16:731-736.
   PubMed Web of Science ®Google Scholar
• BOSTRÖM J, BERGGREN K, ELEBRING T, GREASLEY PJ, WILSTERMANN M: Scaffold hopping, synthesis and structure–activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. Bioorg. Med. Chem. (2007) 15:4077-4084.
   PubMed Web of Science ®Google Scholar
• GIBLIN GM, O'SHAUGHNESSY CT, NAYLOR A et al.:: Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J. Med. Chem. (2007) 50:2597-2600.
   PubMed Web of Science ®Google Scholar
• A-796260: Drug Data Rep. (2006) 28:995.
   Google Scholar
• LAVEY BJ, KOZLOWSKI JA, HIPKIN RW et al.: Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: indentification of a lead and initial SAR studies. Bioorg. Med. Chem. Lett. (2005) 15:783-786.
   PubMed Web of Science ®Google Scholar
• LUNN CA, FINE JS, ROJAS-TRIANA A et al.: A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. (2006) 316:780-788.
   PubMed Web of Science ®Google Scholar
• KAI H, MORIOKA Y, MURASHI T et al.: 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1. Discovery of CB2 receptor selective compounds. Bioorg. Med. Chem. Lett. (2007) 14:4030-4034.
   Google Scholar
• KAI H, MORIOKA Y, MINORU T et al.: 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2. Orally bioavailable compounds. Bioorg. Med. Chem. Lett. (2007) 14:3925-3929.
   Google Scholar
• VINOD KY, HUNGUND BL: Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opin. Ther. Targets (2006) 10:203-210.
   PubMed Web of Science ®Google Scholar
• BIFULCO M, GRIMALDI C, GAZZERRO P, PISANTI S, SANTORO A: Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharm. (2007) 71:1445-1456.
   PubMed Web of Science ®Google Scholar

Patents

• ASKO NOBEL NV: WO2007023143 (2007).
   Google Scholar
• GLENMARK PHARMACEUTICALS LTD: WO2006129178 (2006).
   Google Scholar
• ASTRAZENECA AB: WO2007061360 (2007).
   Google Scholar
• SANOFI: EP576357 (1993).
   Google Scholar
• ASTRAZENECA UK LTD: WO2006067443 (2006).
   Google Scholar
• ASTRAZENECA AB: WO2007010222 (2007).
   Google Scholar
• ASTRAZENECA AB: WO2007010217 (2007).
   Google Scholar
• CAREX SA: WO2006133926 (2006).
   Google Scholar
• SANOFI-AVENTIS: WO2006087480 (2006).
   Google Scholar
• TANABE SEIYAKU CO. LTD: WO2007046550 (2007).
   Google Scholar
• MAKRIYANNIS A, THOTAPALLY R, VEMURI VKR, OLSZEWSKA T: WO2006074445 (2006).
   Google Scholar
• JENRIN DISCOVERY: US20070213302 (2007).
   Google Scholar
• BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO. LTD: WO2007079681 (2007).
   Google Scholar
• SOLVAY PHARMACEUTICALS NV: WO2007071662 (2007).
   Google Scholar
• GLENMARK PHARMACEUTICALS SA: WO2007026215 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2007038045 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2007095513 (2007).
   Google Scholar
• PFIZER PRODUCTS, INC.: WO2006111849 (2006).
   Google Scholar
• TANABE SEIYAKU CO. LTD: WO2007046548 (2007).
   Google Scholar
• ASTRAZENECA PLC: WO2006067428 (2006).
   Google Scholar
• ASTRAZENECA UK LTD: WO2007031721 (2007).
   Google Scholar
• SANOFI-AVENTIS: WO2007068815 (2007).
   Google Scholar
• SANOFI-AVENTIS: WO2007068814 (2007).
   Google Scholar
• SANOFI-AVENTIS: WO2006087476 (2006).
   Google Scholar
• SANOFI-AVENTIS: WO2007000505 (2007).
   Google Scholar
• SANOFI-AVENTIS: WO2006077320 (2006).
   Google Scholar
• SANOFI-AVENTIS: WO2006084975 (2006).
   Google Scholar
• SANOFI-AVENTIS: WO2006070106 (2006).
   Google Scholar
• F. HOFFMANN-LA ROCHE AG: WO2006106054 (2006).
   Google Scholar
• NEUROGEN CORP.: WO2006113704 (2006).
   Google Scholar
• SANOFI-AVENTIS: WO2007006928 (2007).
   Google Scholar
• ASTRAZENECA AB: WO2006101434 (2006).
   Google Scholar
• ASTRAZENECA PLC: WO2007039740 (2007).
   Google Scholar
• NV ORGANON: WO2006100208 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: WO2006138695 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006287341 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006287342 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006287324 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006287323 (2006).
   Google Scholar
• GLENMARK PHARMACEUTICALS: WO2007096764 (2007).
   Google Scholar
• GLENMARK PHARMACEUTICALS: WO2007086080 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2006117307 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006154955 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006154956 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006155126 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB CO.: US2006160850 (2006).
   Google Scholar
• ASTRAZENECA AB: WO2007064272 (2007).
   Google Scholar
• ASTRAZENECA AB: WO2007064273 (2007).
   Google Scholar
• MERCK & CO., INC.: WO2007062193 (2007).
   Google Scholar
• TANABE SEIYAKU CO. LTD: JP20071659270 (2007).
   Google Scholar
• PHARMACIA & UPJOHN CO. LLC: WO2007020502 (2007).
   Google Scholar
• ASTRAZENECA AB: WO2007018459 (2007).
   Google Scholar
• ASTRAZENECA AB: WO2007018460 (2007).
   Google Scholar
• VERNALIS PLC: WO2007057687 (2007).
   Google Scholar
• SCHERING CORP.: WO2007084319 (2007).
   Google Scholar
• SCHERING CORP.: WO2007084450 (2007).
   Google Scholar
• F. HOFFMANN-LA ROCHE AG: WO2006050842 (2006).
   Google Scholar
• F. HOFFMANN-LA ROCHE AG: WO2006136502 (2006).
   Google Scholar
• ACADIA PHARMACEUTICALS, INC.: WO2007047737 (2007).
   Google Scholar
• ABBOTT LABORATORIES: WO2006069196 (2006).
   Google Scholar
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH: WO2007070760 (2007).
   Google Scholar
• FERRINGER BV: WO2005137798 (2005).
   Google Scholar
• FERRING BV: WO2006116399 (2006).
   Google Scholar
• GLAXO GROUP LTD: WO2007017237 (2007).
   Google Scholar
• GLAXO GROUP LTD: WO2007017264 (2007).
   Google Scholar
• GLAXO GROUP LTD: WO2007022937 (2007).
   Google Scholar
• GLAXO GROUP LTD: WO2007022938 (2007).
   Google Scholar
• GLAXO GROUP LTD: WO2007088168 (2007).
   Google Scholar
• PFIZER, INC.: WO2006097808 (2006).
   Google Scholar
• PFIZER, INC.: WO2007102059 (2007).
   Google Scholar
• SANOFI-AVENTIS: WO2007057571 (2007).
   Google Scholar
• SOLVAY PHARMACEUTICALS BV: WO2006087355 (2006).
   Google Scholar
• PHARMOS CORP.: WO2007020631 (2007)
   Google Scholar
• ASTRAZENECA AB: WO2007091950 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2006049880 (2006).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2007044215 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2007035945 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: WO2007001939 (2007).
   Google Scholar
• JANSSEN PHARMACEUTICA NV: US20060223798 (2006).
   Google Scholar
• ADOLOR CORP.: WO0207058960 (2007).
   Google Scholar
• SHIONOGI & CO. LTD: WO2006129609 (2006).
   Google Scholar
• SHIONOGI & CO. LTD: WO2006080284 (2006).
   Google Scholar
• SHIONOGI & CO. LTD: WO2006080287 (2006).
   Google Scholar

Websites

• http://www.organon.com/innovation/pipeline/index.asp A table showing Organon's pipeline (Accessed 28/09/07).
   Google Scholar
• http://www.gwpharm.com/sativex.asp Discussion of the current status of GW Pharmaceuticals' product, Sativex® (Accessed 27/10/07).
   Google Scholar
• http://en.sanofi-aventis.com/press/ppc_18851.asp Discussion of the current status of sanofi-aventis' R&D portfolio (Accessed 28/09/07).
   Google Scholar
• http://www.pharmoscorp.com/index.html Discussion of the current status of Pharmos' pipeline (Accessed 27/10/09).
   Google Scholar
• http://www.fda.gov/ohrms/dockets/ ac/07/briefing/2007-4306b1-fda-backgrounder.pdf FDA briefing document on rimonabant 20 mg (Accessed 28/09/07).
   Google Scholar
• http://en.sanofi-aventis.com/press/ppc_14733.asp#3 Press release from sanofi-aventis with the results of the SERENADE trials (Accessed 27/10/07).
   Google Scholar
• http://en.sanofi-aventis.com/press/ppc_18223.asp Announcement from sanofi-aventis of the withdrawal of rimonabant NDA (Accessed 28/09/07).
   Google Scholar
• http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/32982607en.pdf Press release from the European Medicines Agency detailing the contra-indication of depression or treatment with antidepressants for the prescription of Acomplia® (rimonabant) (Accessed 28/09/07).
   Google Scholar